SKYE — Skye Bioscience Income Statement
0.000.00%
Last trade - 00:00- $25.63m
- -$10.39m
Annual income statement for Skye Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.29 | 7.73 | 18.8 | 35.1 | 30.2 |
| Operating Profit | -6.29 | -7.73 | -18.8 | -35.1 | -30.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.56 | -8.52 | -19.5 | -37.6 | -26.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.56 | -8.52 | -19.5 | -37.6 | -26.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.56 | -8.52 | -19.5 | -37.6 | -26.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.56 | -8.52 | -19.5 | -37.6 | -26.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -7.11 | -5.29 | -6.82 | -5.32 | -0.863 |